EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Potentiating dendritic cell immunotherapy by interrupting the Semaphorin 4D-induced immune-suppressive barrier

Saurabh K Garg, Colin Snyder, Ganesan Ramamoorthi, Krithika N Kodumudi, Elizabeth E Evans, Vincent Lok, Holm Bussler, Jonathan V Nguyen, Jiqiang Yao, Amrita Basu, Namrata Gautam, Julio A Vazquez Martinez und 7 weitere

Cell Reports · 2026

DOI: 10.1016/j.celrep.2026.117050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2026. Verfasst von Saurabh K Garg und 18 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Science Division, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. Hauptthemen laut MEDLINE: Semaphorins, Dendritic Cells, Immunotherapy, Antigens, CD. Die Arbeit nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: US Department of Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune suppression within the tumor microenvironment (TME) remains a significant barrier to effective cancer immunotherapy, including dendritic cell (DC)-based approaches. We address this by targeting Semaphorin 4D (SEMA4D), a pro-tumorigenic mediator expressed by leading-edge tumor cells and host immune cells, particularly in HER2-positive (HER2 pos ) breast cancer (BC). Antibody blockade of SEMA4D enhances the efficacy of adoptively transferred tumor-specific conventional type 1 DCs (cDC1s) across multiple HER2 pos BC models. Tumor-cell-specific ablation of SEMA4D activity amplifies cDC1-driven anti-tumor immunity, highlighting its role in immune evasion. SEMA4D blockade synergizes with cDC1s to increase CD4 + Th1 and other effector cell infiltration into the TME, along with reciprocal elimination of myeloid-derived suppressor cells, fostering robust systemic immune responses that eradicated both local and distant tumors. Given its favorable safety profile, this strategy represents a promising immunotherapy for malignancies, including HER2 pos BC that express high levels of SEMA4D in both tumor and stromal compartments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SemaphorinsDendritic CellsImmunotherapyAntigens, CDBreast NeoplasmsHumansAnimalsFemaleTumor MicroenvironmentCell Line, TumorMice

Stichwörter der Autor:innen

CP: cancerCP: immunologySemaphorin 4Dbreast cancerdendritic cellsimmunotherapytumor microenvironment

Substanzen

SemaphorinsCD100 antigenAntigens, CD

Autor:innen und Institutionen

  • Clinical Science Division, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
  • Vaccinex, Inc., Rochester, NY 14620, USA.
  • Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.
  • Advanced Analytical and Digital Laboratory, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
  • Department of Bioinformatics and Biostatistics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
  • Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Förderung

  • US Department of Defense

Zitieren

APA

Garg, S. K., Snyder, C., Ramamoorthi, G., Kodumudi, K. N., Evans, E. E., Lok, V., Bussler, H., Nguyen, J. V., Yao, J., Basu, A., Gautam, N., Vazquez Martinez, J. A., Chang, D. C., Aldrich, A. L., Wiener, D., Rodriguez, P. C., Zauderer, M., Koski, G. K., & Czerniecki, B. J. (2026). Potentiating dendritic cell immunotherapy by interrupting the Semaphorin 4D-induced immune-suppressive barrier. Cell Reports. https://doi.org/10.1016/j.celrep.2026.117050

Vancouver

Garg SK, Snyder C, Ramamoorthi G, Kodumudi KN, Evans EE, Lok V, et al. Potentiating dendritic cell immunotherapy by interrupting the Semaphorin 4D-induced immune-suppressive barrier. Cell Reports. 2026. doi:10.1016/j.celrep.2026.117050

BibTeX
@article{Garg2026,
  author = {Garg, Saurabh K and Snyder, Colin and Ramamoorthi, Ganesan and Kodumudi, Krithika N and Evans, Elizabeth E and Lok, Vincent and Bussler, Holm and Nguyen, Jonathan V and Yao, Jiqiang and Basu, Amrita and Gautam, Namrata and Vazquez Martinez, Julio A and Chang, Darwin C and Aldrich, Amy L and Wiener, Doris and Rodriguez, Paulo C and Zauderer, Maurice and Koski, Gary K and Czerniecki, Brian J},
  title = {Potentiating dendritic cell immunotherapy by interrupting the Semaphorin 4D-induced immune-suppressive barrier},
  journal = {Cell Reports},
  year = {2026},
  doi = {10.1016/j.celrep.2026.117050}
}
Kostenlos starten →